Study S000784

The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01149421
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 755
Start: 2010-06
Primary completion: 2011-09
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY2189265; DRUG:Placebo
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDN; REGISTRY:CTRI/2010/091/001444

Registered primary outcomes

Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) [Baseline, 16 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008191	Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Ferdinand KC, Cardiovascular diabetology	2023	Systematic review	PMID 36894938 DOI	cites ClinicalTrials.gov:NCT01149421; registry reference DERIVED:36894938